Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cogstate Ltd ( (AU:CGS) ) has shared an update.
Cogstate Ltd has scheduled the release of its half-year results for the period ended 31 December 2025 on 19 February 2026, and will host a live webcast and Q&A for investors on the same day, led by senior executives including the CEO, CFO and Executive Vice President for Clinical Trials. The company will also make a recording of the presentation available via its investor centre within 24 hours, underscoring its efforts to maintain active engagement and transparency with shareholders as it pursues growth in digital cognitive assessment and clinical trial solutions.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is an ASX-listed neuroscience technology company that develops digital tools to optimise brain health assessments, supporting the development of new medicines and earlier clinical insights in healthcare. Its technologies deliver rapid, reliable and sensitive computerised cognitive tests and electronic clinical outcome assessment solutions, alongside quality assurance services, advanced analytics and scientific consulting for clinical trials. Serving biopharmaceutical companies, academic institutions, physicians and patients globally for over two decades, Cogstate is also expanding in the healthcare market with brief, self-administered cognitive tests designed to inform patients while saving physician time.
Average Trading Volume: 306,858
Technical Sentiment Signal: Buy
Current Market Cap: A$374.4M
For an in-depth examination of CGS stock, go to TipRanks’ Overview page.